|
1
|
Novara G, Martignoni G, Artibani W and
Ficarra V: Grading systems in renal cell carcinoma. J Urol.
177:430–436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massari F, Bria E, Maines F, Milella M,
Giannarelli D, Cognetti F, Pappagallo G, Tortora G and Porta C:
Adjuvant treatment for resected renal cell carcinoma: Are all
strategies equally negative? Potential implications for trial
design with targeted agents. Clin Genitourin Cancer. 11:471–476.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keizman D, Rouvinov K, Sella A, Gottfried
M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci
MA, et al: Is there a ‘trial effect’ on outcome of patients with
meta-static renal cell carcinoma treated with sunitinib? Cancer Res
Treat. Mar 5–2015. View Article : Google Scholar : (Epub ahead of
print).
|
|
4
|
van der Mijn JC, Mier JW, Broxterman HJ
and Verheul HM: Predictive biomarkers in renal cell cancer:
Insights in drug resistance mechanisms. Drug Resist Updat.
17:77–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nyhan MJ, O'Sullivan GC and McKenna SL:
Role of the VHL (von Hippel-Lindau) gene in renal cancer: A
multifunctional tumour suppressor. Biochem Soc Trans. 36:472–478.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haroun RA, Zakhary NI, Mohamed MR,
Abdelrahman AM, Kandil EI and Shalaby KA: Assessment of the
prognostic value of methylation status and expression levels of
FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian
patients. Asian Pac J Cancer Prev. 15:4281–4287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daniunaite K, Jarmalaite S, Kalinauskaite
N, Petroska D, Laurinavicius A, Lazutka JR and Jankevicius F:
Prognostic value of RASSF1 promoter methylation in prostate cancer.
J Urol. 192:1849–1855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan JJ and Katan M: PLCɛ and the RASSF
family in tumour suppression and other functions. Adv Biol Regul.
53:258–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wojdacz TK and Dobrovic A:
Methylation-sensitive high resolution melting (MS-HRM): A new
approach for sensitive and high-throughput assessment of
methylation. Nucleic Acids Res. 35:e412007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wierzbicki PM, Klacz J, Rybarczyk A,
Slebioda T, Stanislawowski M, Wronska A, Kowalczyk A, Matuszewski M
and Kmiec Z: Identification of a suitable qPCR reference gene in
metastatic clear cell renal cell carcinoma. Tumour Biol.
35:12473–12487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mikeska T, Candiloro IL and Dobrovic A:
The implications of heterogeneous DNA methylation for the accurate
quantification of methylation. Epigenomics. 2:561–573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Avădănei ER, Wierzbicki PM, Giuşcă SE,
Grigoraş A, Amălinei C and Căruntu ID: Macrophage profile in
primary versus secondary liver tumors. Folia Histochem Cytobiol.
52:112–123. 2014. View Article : Google Scholar
|
|
13
|
van der Weyden L and Adams DJ: The
Ras-association domain family (RASSF) members and their role in
human tumourigenesis. Biochim Biophys Acta. 1776:58–85.
2007.PubMed/NCBI
|
|
14
|
Wierzbicki PM and Rybarczyk A: The Hippo
pathway in colorectal cancer. Folia Histochem Cytobiol. 53:105–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu LJ and Zhang SL: Expression of RASSF1A
in epithelial ovarian cancers. Eur Rev Med Pharmacol Sci.
19:813–817. 2015.PubMed/NCBI
|
|
16
|
Pastuszak-Lewandoska D, Kordiak J,
Migdalska-Sęk M, Czarnecka KH, Antczak A, Górski P, Nawrot E,
Kiszałkiewicz JM, Domańska D and Brzeziańska-Lasota E: Quantitative
analysis of mRNA expression levels and DNA methylation profiles of
three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small
cell lung cancer patients. Respir Res. 16:762015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reeves ME, Firek M, Chen ST and Amaar Y:
The RASSF1 gene and the opposing effects of the RASSF1A and RASSF1C
isoforms on cell proliferation and apoptosis. Mol Biol Int.
2013:1450962013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo W, Cui L, Wang C, Guo Y, Shen S, Kuang
G and Dong Z: Decreased expression of RASSF1A and up-regulation of
RASSF1C is associated with esophageal squamous cell carcinoma. Clin
Exp Metastasis. 31:521–533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peters I, Rehmet K, Wilke N, Kuczyk MA,
Hennenlotter J, Eilers T, Machtens S, Jonas U and Serth J: RASSF1A
promoter methylation and expression analysis in normal and
neoplastic kidney indicates a role in early tumorigenesis. Mol
Cancer. 6:492007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooper CS, Eeles R, Wedge DC, Van Loo P,
Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N,
et al: Analysis of the genetic phylogeny of multifocal prostate
cancer identifies multiple independent clonal expansions in
neoplastic and morphologically normal prostate tissue. Nat Genet.
47:367–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu GS, Lai CY, Xu Y, Bu CF and Su ZX:
Aberrant methylation of RASSF1A gene contribute to the risk of
renal cell carcinoma: A meta-analysis. Asian Pac J Cancer Prev.
16:4665–4669. 2015.PubMed/NCBI
|
|
22
|
de Martino M, Klatte T, Haitel A and
Marberger M: Serum cell-free DNA in renal cell carcinoma: A
diagnostic and prognostic marker. Cancer. 118:82–90. 2012.
View Article : Google Scholar
|
|
23
|
Onay H, Pehlivan S, Koyuncuoglu M, Kirkali
Z and Ozkinay F: Multigene methylation analysis of conventional
renal cell carcinoma. Urol Int. 83:107–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kawai Y, Sakano S, Suehiro Y, Okada T,
Korenaga Y, Hara T, Naito K, Matsuyama H and Hinoda Y: Methylation
level of the RASSF1A promoter is an independent prognostic factor
for clear-cell renal cell carcinoma. Ann Oncol. 21:1612–1617. 2010.
View Article : Google Scholar
|
|
25
|
Hagrass HA, Pasha HF, Shaheen MA, Abdel
Bary EH and Kassem R: Methylation status and protein expression of
RASSF1A in breast cancer patients. Mol Biol Rep. 41:57–65. 2014.
View Article : Google Scholar
|
|
26
|
Nawaz I, Qiu X, Wu H, Li Y, Fan Y, Hu LF,
Zhou Q and Ernberg I: Development of a multiplex methylation
specific PCR suitable for (early) detection of non-small cell lung
cancer. Epigenetics. 9:1138–1148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malpeli G, Amato E, Dandrea M, Fumagalli
C, Debattisti V, Boninsegna L, Pelosi G, Falconi M and Scarpa A:
Methylation-associated down-regulation of RASSF1A and up-regulation
of RASSF1C in pancreatic endocrine tumors. BMC Cancer. 11:3512011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang HL, Zhang Y, Liu P and Zhou PY:
Aberrant promoter methylation of RASSF1A gene may be correlated
with colorectal carcinogenesis: A meta-analysis. Mol Biol Rep.
41:3991–3999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kristensen VN, Lingjærde OC, Russnes HG,
Vollan HK, Frigessi A and Børresen-Dale AL: Principles and methods
of integrative genomic analyses in cancer. Nat Rev Cancer.
14:299–313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Joo MK, Kim KH, Park JJ, Yoo HS, Choe J,
Kim HJ, Lee BJ, Kim JS and Bak YT: CpG island promoter
hypermethylation of Ras association domain family 1A gene
contributes to gastric carcinogenesis. Mol Med Rep. 11:3039–3046.
2015.
|
|
31
|
Hu J, Li H, Shi T, Ma X, Wang B, Xu H, Ai
X, Ju Z, Wang C, Zhang G, et al: Relationship between the
expression of RASSF1A protein and promoter hypermethylation of
RASSF1A gene in bladder tumor. J Huazhong Univ Sci Technolog Med
Sci. 28:182–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tezval H, Merseburger AS, Matuschek I,
Machtens S, Kuczyk MA and Serth J: RASSF1A protein expression and
correlation with clinicopathological parameters in renal cell
carcinoma. BMC Urol. 8:122008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reeves ME, Baldwin SW, Baldwin ML, Chen
ST, Moretz JM, Aragon RJ, Li X, Strong DD, Mohan S and Amaar YG:
Ras-association domain family 1C protein promotes breast cancer
cell migration and attenuates apoptosis. BMC Cancer. 10:5622010.
View Article : Google Scholar : PubMed/NCBI
|
